...
首页> 外文期刊>Allergy >The potential of anti‐infectives and immunomodulators as therapies for asthma and asthma exacerbations
【24h】

The potential of anti‐infectives and immunomodulators as therapies for asthma and asthma exacerbations

机译:抗感染性和免疫调节剂的潜力作为哮喘和哮喘的疗法

获取原文
获取原文并翻译 | 示例
           

摘要

Abstract Asthma is responsible for approximately 25,000 deaths annually in Europe despite available medicines that maintain asthma control and reduce asthma exacerbations. Better treatments are urgently needed for the control of chronic asthma and reduction in asthma exacerbations, the major cause of asthma mortality. Much research spanning 20 years shows a strong association between microorganisms including pathogens in asthma onset, severity and exacerbation, yet with the exception of antibiotics, few treatments are available that specifically target the offending pathogens. Recent insights into the microbiome suggest that modulating commensal organisms within the gut or lung may also be a possible way to treat/prevent asthma. The European Academy of Allergy & Clinical Immunology Task Force on Anti‐infectives in Asthma was initiated to investigate the potential of anti‐infectives and immunomodulators in asthma. This review provides a concise summary of the current literature and aimed to identify and address key questions that concern the use of anti‐infectives and both microbe‐ and host‐based immunomodulators and their feasibility for use in asthma.
机译:摘要哮喘仍然在欧洲负责约25,000人死亡,尽管可用于维持哮喘控制并减少哮喘恶化的药物。迫切需要对慢性哮喘进行控制,迫切需要更好的治疗,并降低哮喘恶化,哮喘死亡率的主要原因。许多研究跨越& 20年显示微生物之间的强烈关联,包括哮喘发作的病原体,严重程度和恶化,但除了抗生素外,还有很少的治疗方法,可专门针对违规病原体。最近进入微生物组的见解表明,调节肠道或肺部内的共生生物也可能是治疗/预防哮喘的可能方法。欧洲过敏院&启动临床免疫学专案上的抗感染者的抗病,以研究哮喘抗感染性和免疫调节剂的潜力。本综述提供了目前文献的简明摘要,旨在识别和解决涉及使用抗感染性和基于微生物和宿主的免疫调节剂的关键问题及其在哮喘中使用的可行性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号